BCLSI
PHVS icon

Bain Capital Life Sciences Investors’s Pharvaris PHVS Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.6M Sell
2,675,509
-126,572
-5% -$3.38M 6.82% 5
2025
Q4 		$77.8M Sell
2,802,081
-379,194
-12% -$9.13M 5.96% 5
2025
Q3 		$79.4M Sell
3,181,275
-122,106
-4% -$2.71M 5.27% 4
2025
Q2 		$58.1M Hold
3,303,381
– – 7.27% 4
2025
Q1 		$51.9M Hold
3,303,381
– – 7.67% 3
2024
Q4 		$63.3M Hold
3,303,381
– – 7.45% 3
2024
Q3 		$61.2M Hold
3,303,381
– – 6.37% 6
2024
Q2 		$62.1M Hold
3,303,381
– – 6.82% 5
2024
Q1 		$76.3M Sell
3,303,381
-600,938
-15% -$16M 6.14% 6
2023
Q4 		$110M Sell
3,904,319
-880,355
-18% -$17.8M 10.5% 3
2023
Q3 		$99.9M Sell
4,784,674
-84,110
-2% -$1.55M 11.17% 2
2023
Q2 		$73.7M Buy
4,868,784
+1,688,183
+53% +$16.3M 7.59% 4
2023
Q1 		$25.6M Hold
3,180,601
– – 3.2% 11
2022
Q4 		$35.8M Hold
3,180,601
– – 4% 9
2022
Q3 		$24.4M Hold
3,180,601
– – 2.91% 12
2022
Q2 		$70.3M Hold
3,180,601
– – 8.24% 3
2022
Q1 		$57.7M Hold
3,180,601
– – 5.6% 4
2021
Q4 		$45.8M Hold
3,180,601
– – 3.63% 9
2021
Q3 		$56.4M Hold
3,180,601
– – 3.5% 11
2021
Q2 		$59.3M Hold
3,180,601
– – 3.88% 8
2021
Q1 		$89M Buy
+3,180,601
New +$100M 5.04% 6

Other funds holding PHVS

GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
EFM
EQT Fund Management Luxembourg $1.02B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Bain Capital Life Sciences Investors's PHVS Position: Q1 2026 in Review

Bain Capital Life Sciences Investors reduced its Pharvaris (PHVS) stake by 4.5% in Q1 2026, selling an estimated $3.38M and leaving 2,675,509 shares worth $75.6M. The position accounts for 6.82% of the portfolio, ranked #5.

Bain Capital Life Sciences Investors first reported a position in PHVS in Q1 2021 and has held it in 21 quarters since. The position peaked at $110M in Q4 2023. 110 funds tracked by Wall St. Rank hold PHVS as of Q1 2026.

  • Bain Capital Life Sciences Investors held 2,675,509 shares of Pharvaris worth $75.6M as of Q1 2026.
  • Bain Capital Life Sciences Investors sold 126,572 Pharvaris shares in Q1 2026, an estimated $3.38M.
  • Pharvaris made up 6.82% of Bain Capital Life Sciences Investors's portfolio in Q1 2026, its #5 holding.
  • Bain Capital Life Sciences Investors first reported a position in Pharvaris in Q1 2021 and has held it in 21 quarters since.
  • Bain Capital Life Sciences Investors's Pharvaris position peaked at $110M in Q4 2023.
  • 110 funds tracked by Wall St. Rank held Pharvaris as of Q1 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2026, filed 15 May 2026.